Where is Genmab A/S headquartered?

Genmab A/S is recorded with headquarters in Valby, DK in NovaPharmaNews public regulatory and sponsor datasets.

Is Genmab A/S publicly traded?

Genmab A/S is represented in our database primarily through regulatory marketing authorisation or trial sponsor records; it may not have a US listed ticker in SEC EDGAR.

What drugs are associated with Genmab A/S?

No drug profiles are currently linked to Genmab A/S; check pipeline programs or search the drug directory.

What clinical trials is Genmab A/S sponsoring?

Genmab A/S is linked to 29 pipeline program(s) sourced from ClinicalTrials.gov and EU CTIS where sponsor names match.

What patents list Genmab A/S as applicant?

No US patent records are currently linked to this company profile.

What pipeline phases does Genmab A/S have in our database?

Phase distribution from linked programs: phase 2: 18, phase 1: 6, phase 3: 5.

Where does NovaPharmaNews source data on Genmab A/S?

Profiles combine SEC EDGAR (US issuers), FDA openFDA, EMA medicines data, ClinicalTrials.gov, EU CTIS, USPTO PatentsView, and regional PBS/PMDA/NMPA feeds. See /about/data-sources.

Is Genmab A/S data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

Is Genmab A/S data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

Is Genmab A/S data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

Genmab Pharmaceuticals Company Profile | Pipeline, Drugs, Clinical…

Name: Genmab intelligence dataset
Creator: NovaPharmaNews
License: https://www.sec.gov/edgar.shtml

Company details

Status: Public
HQ: Carl Jacobsens Vej 30, 2500 Valby, DK
Employees: 2,847
Programs: 29
Drugs: 56
Patents: 0

Official website ↗ All projects Drug pipeline News & analysis

Quick answer

Genmab A/S is a pharma organization headquartered in Valby, DK. Primary therapeutic focus areas include Lymphoma of B-cell origin, Malignant Solid Tumors, Metastatic or advanced malignant solid tumors, Non-Small Cell Lung Cancer, Chronic Lymphocytic Leukemia. NovaPharmaNews links 29 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (18), phase 1 (6), phase 3 (5).

Company snapshot

We are an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. Long recognized for our expertise in antibody innovation, our passionate and collaborative team has pioneered antibody-based formats, including bispecific antibodies, antibody-drug conjugates, immune-modulating antibodies, and other

29 active pipeline program(s) linked via ClinicalTrials.gov.
29 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Genmab. Not investment advice.

Top assets

View drugs (56) View projects (29)

Lead pipeline drugs

abraxane
Marketed / approved
amlexanox
approved
anakinra
approved
anti-
Marketed / approved

Active clinical programs

GCT1046-06 Non-Small Cell Lung Cancer
Phase 3
GCT1184-02 Platinum-resistant Ovarian Cancer
Phase 3
GCT1184-03 Endometrial Cancer Advanced, Recurrent, Metastatic, or Primary Unresectable Endometrial Cancer
Phase 3
GCT3013-05 B-cell Lymphoma
Phase 3

Momentum

Proprietary activity score for Genmab.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

Clinical trials 5 30d
Nova articles 0 30d
Patents filed 0 30d
FDA actions 0 30d
SEC filings 0 30d
Conference presentations 0 90d
Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Peer + 0 momentum

AstraZeneca

TA overlap score 40
Peer + 0 momentum

BEONE MEDICINES AUS

TA overlap score 40
Peer + 0 momentum

Zentalis Pharmaceuticals

TA overlap score 22.8
Peer + 0 momentum

BeiGene

TA overlap score 22.8
Peer + 0 momentum

Aptevo Therapeutics

TA overlap score 21.8

Recent activity

Latest pipeline, patent, and corporate events for Genmab.

Jun 8, 2026 Clinical update
GCT3014-01 — Phase 2
Jun 8, 2026 Clinical update
GCT1079-01 — Phase 1
Jun 8, 2026 Clinical update
GCT1057-01 — Phase 1
Jun 8, 2026 Clinical update
GCT1056-01 — Phase 1
Jun 8, 2026 Clinical update
GCT1046-07 — Phase 2

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

What is Genmab?

Genmab A/S is a pharma organization headquartered in Valby, DK. Primary therapeutic focus areas include Lymphoma of B-cell origin, Malignant Solid Tumors, Metastatic or advanced malignant solid tumors, Non-Small Cell Lung Cancer, Chronic Lymphocytic Leukemia. NovaPharmaNews links
Is Genmab publicly traded?

Genmab appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.
What drugs does Genmab develop or market?

We link 56 drug profile(s) where Genmab is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/genmab-a-s#company-drugs.
What are the latest developments for Genmab?

In the last 12 months our linked public records show 29 trial program update(s) and 0 US patent grant(s) tied to this profile.
What therapeutic areas does Genmab focus on?

Genmab focuses on Lymphoma of B-cell origin, Malignant Solid Tumors, Metastatic or advanced malignant solid tumors based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others

Oncology

Quick answer

Company snapshot

Top assets

Lead pipeline drugs

Active clinical programs

Momentum

Signal breakdown

Competitor landscape

Recent activity

Quick answers

Therapeutic area distribution

Programs by therapeutic area

Stay Ahead in Pharma